Norinchukin Bank The grew its stake in Johnson & Johnson (NYSE:JNJ) by 7.4% during the third quarter, according to its most recent 13F filing with the SEC. The firm owned 381,758 shares of the company’s stock after acquiring an additional 26,245 shares during the period. Johnson & Johnson comprises 1.0% of Norinchukin Bank The’s investment portfolio, making the stock its 9th biggest holding. Norinchukin Bank The’s holdings in Johnson & Johnson were worth $49,632,000 as of its most recent filing with the SEC.
Several other institutional investors also recently added to or reduced their stakes in JNJ. ING Groep NV increased its stake in Johnson & Johnson by 11.8% during the 3rd quarter. ING Groep NV now owns 676,388 shares of the company’s stock worth $87,937,000 after buying an additional 71,614 shares during the period. D.A. Davidson & CO. increased its stake in Johnson & Johnson by 0.5% during the 3rd quarter. D.A. Davidson & CO. now owns 538,338 shares of the company’s stock worth $69,989,000 after buying an additional 2,937 shares during the period. Rodgers Brothers Inc. increased its stake in Johnson & Johnson by 1.4% during the 3rd quarter. Rodgers Brothers Inc. now owns 67,780 shares of the company’s stock worth $8,812,000 after buying an additional 961 shares during the period. Pinnacle Financial Partners Inc. increased its stake in Johnson & Johnson by 2.8% during the 3rd quarter. Pinnacle Financial Partners Inc. now owns 81,215 shares of the company’s stock worth $10,559,000 after buying an additional 2,177 shares during the period. Finally, Zurcher Kantonalbank Zurich Cantonalbank increased its stake in Johnson & Johnson by 1.2% during the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 1,068,272 shares of the company’s stock worth $138,886,000 after buying an additional 12,608 shares during the period. 65.58% of the stock is currently owned by institutional investors and hedge funds.
In other news, VP Paulus Stoffels sold 155,342 shares of the company’s stock in a transaction on Thursday, February 15th. The shares were sold at an average price of $129.86, for a total value of $20,172,712.12. Following the completion of the transaction, the vice president now owns 357,906 shares in the company, valued at approximately $46,477,673.16. The sale was disclosed in a document filed with the SEC, which is available at this link. Corporate insiders own 0.19% of the company’s stock.
Shares of Johnson & Johnson (NYSE:JNJ) opened at $132.02 on Friday. Johnson & Johnson has a 52-week low of $120.90 and a 52-week high of $148.32. The company has a debt-to-equity ratio of 0.51, a current ratio of 1.41 and a quick ratio of 1.02. The company has a market cap of $354,670.00, a P/E ratio of 24.31, a price-to-earnings-growth ratio of 2.18 and a beta of 0.74.
Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings data on Tuesday, January 23rd. The company reported $1.74 EPS for the quarter, beating the Zacks’ consensus estimate of $1.72 by $0.02. Johnson & Johnson had a net margin of 1.70% and a return on equity of 29.00%. The company had revenue of $20.20 billion for the quarter, compared to the consensus estimate of $20.08 billion. During the same period in the prior year, the firm posted $1.58 EPS. The company’s quarterly revenue was up 11.5% compared to the same quarter last year. equities research analysts anticipate that Johnson & Johnson will post 8.11 earnings per share for the current year.
The business also recently announced a quarterly dividend, which will be paid on Tuesday, March 13th. Stockholders of record on Tuesday, February 27th will be issued a $0.84 dividend. This represents a $3.36 annualized dividend and a dividend yield of 2.55%. The ex-dividend date of this dividend is Monday, February 26th. Johnson & Johnson’s payout ratio is 61.88%.
Several brokerages recently weighed in on JNJ. Vetr raised shares of Johnson & Johnson from a “buy” rating to a “strong-buy” rating and set a $152.28 target price on the stock in a research note on Monday, February 5th. Stifel Nicolaus upped their target price on shares of Johnson & Johnson from $142.00 to $145.00 and gave the stock a “hold” rating in a research note on Wednesday, January 24th. BTIG Research reaffirmed a “sell” rating and set a $110.00 target price on shares of Johnson & Johnson in a research note on Wednesday, January 24th. Credit Suisse Group set a $154.00 target price on shares of Johnson & Johnson and gave the stock a “hold” rating in a research note on Monday, January 22nd. Finally, Wells Fargo & Co reaffirmed an “outperform” rating and set a $160.00 target price (up from $155.00) on shares of Johnson & Johnson in a research note on Friday, January 12th. Four research analysts have rated the stock with a sell rating, eight have given a hold rating, nine have assigned a buy rating and one has assigned a strong buy rating to the stock. The stock presently has a consensus rating of “Hold” and an average target price of $146.16.
COPYRIGHT VIOLATION WARNING: “Johnson & Johnson (JNJ) Shares Bought by Norinchukin Bank The” was originally published by Transcript Daily and is owned by of Transcript Daily. If you are accessing this story on another domain, it was stolen and republished in violation of United States & international copyright & trademark laws. The correct version of this story can be accessed at https://transcriptdaily.com/2018/02/25/johnson-johnson-jnj-shares-bought-by-norinchukin-bank-the.html.
About Johnson & Johnson
Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being.
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.